Corona Remedies
Mainboard₹14,868 / 14 Shares
IPO Live Subscription Details
| Category | Subscription (Times) |
|---|---|
| Date | 10 Dec 2025, 05:57 PM |
| QIBs | 293.80 times |
| NII | 220.18 times |
| Retail | 30.29 times |
| Employee | 15.56 times |
| Total | 144.49 times |
Corona Remedies IPO Details
The Corona Remedies IPO price band is set between ₹1008-1062 per equity share, with a face value of ₹10 per share. The issue is managed by Bigshare Services Pvt Ltd, and the equity shares are proposed to be listed on the Mainboard.
The IPO date for subscription opens on 8 Dec, 2025 and closes on 10 Dec, 2025. Investors can check the allotment status on 11 Dec, 2025, while the listing date is tentatively scheduled for 15 Dec, 2025.
The total issue size is 61,71,101 shares, aggregating up to ₹655.37 crore. Stay tuned for the latest Corona Remedies IPO review and GMP updates.
Corona Remedies IPO Review, Rating & Analysis
Corona Remedies IPO Review
NeutralCorona Remedies IPO Rating
Corona Remedies IPO Highlights
IPO Date
Dec 8, 2025 - Dec 10, 2025
Listing Date
15 Dec, 2025
Face Value
₹10 Per Equity Share
Price Band
₹1008-1062 per equity share
Lot Size
14 Shares
Fresh Issue
Shares
Offer for Sale
-
Listing At
BSE, NSE
Corona Remedies IPO Lot Size
The minimum market lot for Corona Remedies IPO is 14 shares with an application amount of ₹14,868. Retail investors can apply for up to 13 lots. The table below details the minimum and maximum investment limits for Retail and HNI investors.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
| S-HNI (Max) | 67 | 938 | ₹9,96,156 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024 |
Corona Remedies IPO Timeline
Issue Price
₹1008-1062 per equity shareFace Value
₹10 Per Equity ShareListing at Group
BSE, NSERegistrar
Bigshare Services Pvt LtdLead Manager
JM Financial LtdIIFL Capital Services LtdKotak Mahindra Capital Co.LtdKotak Mahindra Capital Co.Ltd.Issue Size
61,71,101 shares(aggregating up to ₹655.37 crore)Corona Remedies IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 30-Jun-25 | 1012.38 | 348.56 | 46.20 | 607.02 | 545.86 | 106.65 |
| 31-Mar-25 | 929.86 | 1202.35 | 149.43 | 606.34 | 545.18 | 62.70 |
| 31-Mar-24 | 830.58 | 1020.93 | 90.50 | 480.41 | 419.25 | 134.14 |
| 31-Mar-23 | 595.02 | 891.10 | 84.93 | 408.52 | 347.36 | 2.33 |
In Cr.
Corona Remedies IPO Reservation Details
| Investor Category | Shares Offered | % Shares |
|---|---|---|
| Anchor Investor Shares Offered | 1834804 | 29.73% |
| QIB Shares Offered | 1221729 | 19.8% |
| NII (HNI) Shares Offered | 916960 | 14.86% |
| bNII > ₹10L | 611307 | 10% |
| sNII < ₹10L | 305653 | 5% |
| Retail Shares Offered | 2139573 | 10% |
| Employee Shares Offered | 58036 | 0.94% |
| Total Shares Offered | 6171101 | 100% |
Corona Remedies IPO Documents
Corona Remedies IPO Valuations
EPS Pre IPO
₹24.43/-EPS Post IPO
₹30.21/-PE Pre IPO
43.47PE Post IPO
35.15ROE
27.50%ROCE
41.32%Debt Equity
0.10RoNW
24.65%PAT Margin
12.49%Price to Book Value
10.71Corona Remedies Peer Comparison
| Company Name | Revenue | RoNW | PE Ratio | PB Ratio |
|---|---|---|---|---|
| Corona Remedies | 1196 | 24.6% | N/A | N/A |
| Abbott India | 6409 | 33.4% | 45.1 | N/A |
| Alkem Lab | 12964 | 18.0% | 31.3 | N/A |
| Eris Life | 2893 | 12.2% | 61.8 | N/A |
| Glaxosmithkline | 3749 | 47.5% | 46.8 | N/A |
| J B Chemicals | 3917 | 19.2% | 42.6 | N/A |
| Mankind | 12207 | 13.8% | 45.7 | N/A |
| Pfizer | 2281 | 18.2% | 29.6 | N/A |
| Sanofi | 2013 | 48.0% | 24.4 | N/A |
| Torrent | 11516 | 25.1% | 65.9 | N/A |
Promoters & Share Holding
Promoter(s) Name
- Dr. Kirtikumar Laxmidas Mehta
- Niravkumar Kirtikumar Mehta
- Ankur Kirtikumar Mehta
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| 72.50% | N/A% |
About Company
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas.
The diversified portfolio of the company as of December 2024 comprises 67 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, including vitamins/minerals/nutrition, gastrointestinal, and respiratory.The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, thus consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
Presently, the company owns two manufacturing facilities located in the states of Gujarat.
As of December 31, 2024, the company had 88 R&D employees.
Corona Remedies IPO Subscription Details
| As on | QIB | NII bNII sNII | Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 12,21,729 | 9,16,960
6,11,307
3,05,653
| 21,39,573 | 43,36,298 |
Day 108-12-25 05:00 PM | 0.00 x | 0.84
0.53 x
1.45 x
| 0.93 x | 0.66 x |
Day 209-12-25 05:00 PM | 1.76 x | 28.32
29.02 x
26.92 x
| 6.81 x | 9.90 x |
Day 310-12-25 05:00 PM | 293.80 x | 220.18
246.67 x
167.20 x
| 30.29 x | 144.49 x |
Retail:24.82x
BHNI:49.77x
SHNI:160.35x
Company Contact Details
Corona Remedies
CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat, 380059Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/
Registrar Contact Details
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Frequently Asked Questions about Corona Remedies IPO
When will Corona Remedies IPO open for subscription?
The Corona Remedies IPO opens on 8 Dec, 2025 and closes on 10 Dec, 2025.
What is the investors portion for Corona Remedies IPO?
The investors' portion for QIB is 293.80 x, NII is 246.67 x, and Retail is 30.29 x.
How to apply for Corona Remedies IPO?
You can apply for Corona Remedies IPO via ASBA online through your bank account. You can also apply via UPI through stock brokers like Zerodha, Upstox, or Paytm Money.
What is the issue size of Corona Remedies IPO?
The issue size of Corona Remedies IPO is approx ₹61,71,101 shares(aggregating up to ₹655.37 crore) crores.
What is the price band of Corona Remedies IPO?
The price band for Corona Remedies IPO is ₹1008 to ₹1062 per equity share.
What is the lot size of Corona Remedies IPO?
The minimum bid (lot size) for Corona Remedies IPO is 14 shares with an investment of approx ₹14,868 .
What is the allotment date of Corona Remedies IPO?
The allotment date for Corona Remedies IPO is 11 Dec, 2025.
What is the listing date of Corona Remedies IPO?
The listing date for Corona Remedies IPO is expected to be 15 Dec, 2025.
What is the GMP of Corona Remedies IPO?
The latest Grey Market Premium (GMP) for Corona Remedies IPO is being updated regularly on IPOROCK.
Parth D.
Founder & Lead Analyst
Parth D. is a software engineer and financial analyst who brings a quantitative edge to IPO tracking. With deep expertise in algorithmic trading and financial tool development, he builds the technology that powers IPORock's real-time data engines. He has been tracking the Indian market since 2018.